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ABSTRACT 
 
Background 
The immune modulating properties of statins may benefit smokers with asthma. We 
tested the hypothesis that short-term treatment with atorvastatin improves lung 
function or indices of asthma control in smokers with asthma. 
Methods 
Seventy one smokers with mild to moderate asthma were recruited to a randomized 
double-blind parallel group trial comparing treatment with atorvastatin (40 mg per 
day) versus placebo for 4 weeks. After 4 weeks treatment inhaled beclometasone (400 
µg per day) was added to both treatment arms for a further 4 weeks. The primary 
outcome was morning peak expiratory flow after 4 weeks treatment.  Secondary 
outcome measures included indices of asthma control and airway inflammation. 
Results 
At 4 weeks, there was no improvement in the atorvastatin group compared to the 
placebo group in morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 
17.37, p=0.449], but there was an improvement with atorvastatin in asthma quality of 
life score [0.52, 95% CI 0.17 to 0.87 p=0.005]. There was no significant improvement 
with atorvastatin and inhaled beclometasone compared to inhaled beclometasone 
alone in outcome measures at 8 weeks.  
Conclusions 
Short-term treatment with atorvastatin does not alter lung function but may improve 
asthma quality of life in smokers with mild to moderate asthma.  
Clinicaltrials.gov identifier: NCT00463827 
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BACKGROUND 
 
Smokers with asthma have poor symptom control, accelerated decline in lung 
function and an attenuated response to inhaled corticosteroids compared to non-
smokers with asthma[1-4].  Optimum medical therapy for smokers with asthma has 
not been established. There is an unmet need for alternative or additional drugs for 
smokers with asthma who are unable to stop smoking.  
 
In addition to reducing cholesterol biosynthesis by inhibiting 3-hydroxy-3-
methylgluteryl coenzyme A (HMG-CoA) reductase, statins have pleiotropic anti-
inflammatory effects[5] that may be beneficial in the treatment of chronic 
inflammatory diseases[5, 6]. Preclinical in vitro and in vivo studies, including 
experimental models of allergic lung inflammation[7, 8], have shown that statins 
reduce components of airway inflammation potentially relevant to the pathogenesis of 
asthma. Despite preliminary data showing an absence of clinical benefit with short-
term statin therapy on asthma symptoms or lung function in non-smokers with 
asthma[9-11], there is indirect evidence to suggest that statins may show efficacy in 
patients with asthma who smoke. First, simvastatin inhibits lung parenchymal 
destruction, peribronchial and perivascular inflammatory cell infiltrate and leads to a 
reduction in levels of matrix metalloproteinase-9 in a rat model of smoking related 
lung disease[12] and reduces airway inflammation and reverses elastase-induced 
pulmonary emphysema in mice[13]. Second, statins enhance corticosteroid sensitivity 
in asthma[14, 15], possibly by restoring histone deacetylase (HDAC) activity[16], 
which is reduced by cigarette smoking[17]. Thirdly, retrospective or case cohort 
studies have shown statin use is associated with a reduced decline in lung function in 
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cigarette smokers[18] and reduced exacerbation rates, hospital admission  and 
mortality in patients with COPD[19]. Taken together, this evidence suggests that 
statin treatment may improve asthma control in smokers with asthma. This study 
aimed to test the hypothesis that short term treatment with atorvastatin, either alone or 
in addition to low dose inhaled corticosteroid improves lung function or other indices 
of asthma control and/or airway inflammation in smokers with asthma.  Atorvastatin 
was chosen because of its favourable in vitro and in vivo anti-inflammatory properties 
[20-22] and evidence of clinical benefit at the dose of 40 mg daily in rheumatoid 
arthritis [21]. 
 
METHODS  
 
Study subjects    
Cigarette smokers with chronic asthma symptoms of more than one year duration, 
aged 18 to 60 years were eligible to take part. Participants were regular smokers with 
a history of 5 pack years or more. Patients were recruited from general practice, 
hospital clinics and research databases. Smoking cessation advice was offered at the 
study screening visit and eligible subjects who were not willing to quit were enrolled. 
Patients were excluded if they were already taking a statin or medications known to 
interact with statins such as antifungal agents, macrolide antibiotics, cyclosporin, 
gemfibrozil, verapamil and amiodarone. All subjects demonstrated reversibility in 
FEV1 following salbutamol of ≥12% and ≥200ml or PC20 ≤ 8mg/ml or ≥ 20% 
variability in peak expiratory flow (PEF)[23]. The West Glasgow Research Ethics 
Committee approved the study and all patients gave written informed consent. 
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Study design  
The aim of the study was to test the hypothesis that short-term treatment with 
atorvastatin improves lung function or indices of asthma control or airway 
inflammation in smokers with asthma. Patients had been free of exacerbation and 
lower respiratory tract infection for a minimum period of 6 weeks prior to 
randomisation. Where relevant, inhaled corticosteroid (ICS) and long-acting 
bronchodilator (LABA) treatment were weaned over a 4-10 week period. On 
completion of a two-week run in period free from ICS and LABA, a baseline visit was 
performed. Subjects recorded their PEF and asthma symptoms twice daily throughout 
the study. Randomization was conducted via an interactive telephone service (IVRS) 
in randomised blocks of length four.  Patients were assigned to eight weeks of 
atorvastatin 40mg daily or a matched placebo.  After four weeks inhaled 
beclometasone (Clenil® Modulite® 200 µg twice daily) was also commenced in both 
randomised groups. Treatment with short-acting β-2 agonist was allowed throughout 
the study. At baseline, 4 and 8 week visits, electronic PEF data were downloaded and 
spirometry performed. At these visits patients completed a validated asthma control 
questionnaire (ACQ) and asthma quality of life questionnaire (AQLQ); induced 
sputum was performed and exhaled nitric oxide was measured.  At baseline and 8 
weeks, blood samples were taken for immunological tests, lipids and liver 
transaminases.   
 
Measurements 
PEF was recorded using Piko-1 electronic peak flow meters (nSpire Hertford UK) and 
symptoms were recorded in a validated diary card[24]. ACQ[25] and AQLQ [total 
and individual domains][26] results were also recorded. The total AQLQ score is the 
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mean of all 32 responses and the individual domain scores are the means of the items 
in those domains. A change in score of 0.5 is the smallest change that is considered 
clinically important. Exhaled nitric oxide (NO) levels were measured at 50ml/s in 
concordance with standardised guidelines[27] (Niox Flex, Aerocrine, Sweden). 
Spirometry was performed to American Thoracic Society guidelines. Exhaled carbon 
monoxide levels were measured by hand held Smokerlyser. (Bedford scientific, UK). 
Airway hyper-responsiveness was measured by Cockcroft’s methacholine challenge 
test with concentrations from 0.03mg/ml to 16 mg/ml[28]. Blood samples were 
processed by local accredited laboratories for urea and electrolytes, liver 
transaminases, thyroid function, creatinine kinase levels and lipid profile; 
haematological testing (full blood count), and total IgE and specific IgE to cat, house 
dust mite and grass. Total IgE levels >120 IU/ml was considered elevated and specific 
IgE levels >0.35 AU/ml was used to define atopic status. Sputum induction was 
performed as previously described[29], using a low concentration of DTT (0.003%) to 
disperse cells without undue effects on mediator measurements. Sputum supernatant 
fluid was analysed for leukotriene (LT) B4 and myeloperoxidase (MPO) using enzyme 
immunoassay (EIA) (LTB4 from R&D Systems, Abingdon, UK, MPO from 
Cambridge Bioscience, Cambridge, UK.), and interleukin (IL)-2, 4, 6, 8, 10 and tumor 
necrosis factor (TNF)-α using a Luminex microbead fluorescence kit (Biosource, 
Invitrogen, Paisley, UK). Serum was analysed for high sensitivity (hs)-CRP by EIA 
(R & D Systems) and sICAM-1, E-selectin, P-selectin, IL-2, 4, 6, 8, 10 and TNF-α 
using a multiplex fluorescence bead kit (sICAM-1, E-selectin and P-selectin from 
Merck Chemicals, Hertfordshire, UK. Interleukins and TNF-α by Biosource). Current 
smoking was confirmed by serum cotinine measurement (Cozart, Oxfordshire, UK). 
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Treatment compliance was assessed by tablet count and inhaler weight. Adverse event 
information was reviewed at each study visit. 
 
Analysis  
Baseline characteristics were described by number and percentage of patients for 
categorical variables and mean (SD) or median and inter-quartile range for normally 
distributed or skewed continuous variables respectively.  The full analysis set was 
defined as all randomized subjects with at least one post-baseline assessment of PEF 
(primary endpoint).  The primary endpoint was calculated as the mean of the 
morning PEF measurements from the Piko-1 electronic peak flow meter recordings 
during the seven days immediately preceding each study visit. If fewer than three days 
of data were recorded within that period, patient diary entries for morning PEF were 
substituted in place of the missing values. The mean was then calculated if there were 
at least three days of data available, otherwise the response was taken to be missing. 
Response to atorvastatin on lung function, diary data, induced sputum, mediator levels 
and exhaled nitric oxide versus placebo was assessed by analysis of covariance, where 
the response was change from baseline and the baseline value was the covariate. All 
data were analysed using SAS version 9 (SAS Institute, Cary, NC). A sample size of 
68 was calculated to have 80% power to detect a mean difference of 25L/min in 
change from baseline to four weeks in morning PEF, the primary endpoint[30], 
assuming a standard deviation of changes of 36L/min, using a two sample t-test with a 
5% two-sided significance level. Recruitment of 74 patients was planned to ensure 
that 68 patients completed the study. 
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RESULTS  
 
Recruitment and baseline characteristics 
Of the 286 subjects contacted, 131 volunteers were consented and 71 were 
randomized to either the atorvastatin treatment group (n=36) or the placebo group 
(n=35) (Figure 1). Baseline demographic and clinical characteristics of patients are 
listed in Tables 1 and 2.  The two groups were well balanced with respect to these 
characteristics. 
 
Changes in clinical outcomes 
Changes in clinical outcomes after atorvastatin treatment are listed in Table 2 and 
illustrated in Figure 2.  At 4 weeks, the change in mean morning PEF, as compared 
with baseline, did not differ substantially between the atorvastatin and placebo 
treatment periods [mean difference -10.67 L/min, 95% CI -38.70 to 17.37, p=0.449]. 
There was an improvement in the atorvastatin group compared to the placebo group at 
4 weeks in the ACQ score [-0.37, 95% CI -0.67 to -0.07, p=0.016] and AQLQ total 
score [0.52, 95% CI 0.17 to 0.87 p=0.005] as well as AQLQ symptoms domain [0.63, 
95% CI 0.18 to 1.09 P=0.007], activity limitations domain [0.40, 95% CI 0.10 to 0.71 
P=0.010] and emotional functions domain [0.60, 95% CI 0.10 to 1.09) P=0.019]. At 8 
weeks there was no significant improvement with atorvastatin and inhaled 
beclometasone compared to inhaled beclometasone alone in primary or exploratory 
outcome measures.  
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Changes in inflammatory biomarkers 
After 4 and 8 weeks, the total cell count and differential cell counts in induced sputum 
were similar for atorvastatin and placebo (Table 3). The sputum and serum 
concentrations of inflammatory cytokines and mediators were similar after 
atorvastatin compared to after placebo treatment at the 4 week and 8 week time points 
(Table 3 and data not shown). There was no significant change in FENO after 
atorvastatin compared to placebo (data not shown). 
 
Change in biochemical markers  
The biochemical effects of atorvastatin therapy were reflected in significant reduction 
in concentration of serum lipids; cholesterol [-1.55, 95% CI -1.88 to -1.23 P<0.0001], 
LDL-cholesterol [-1.50, 95% CI -1.88 to -1.13 P<0.0001] and triglyceride [-0.49, 95% 
CI -0.87, -0.11 P=0.013] (Table 4).  
 
Adverse events  
No suspected unexpected serious adverse reactions (SUSARs) were recorded.  
Adverse events (AEs) were similar between treatment groups. Two serious adverse 
events occurred, one in each group and neither related to study drug.  For adverse 
events greater than 5% in frequency, the only severe AE was back pain in 3 (8.3%) 
subjects in the atorvastatin group versus 0 in the placebo group.  Moderate side effects  
were more frequent in the atorvastatin group: oral candidiasis (2 subjects versus 0), 
neck pain (2 versus 0) and asthma worsening (2 versus 1).   
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Compliance  
Compliance assessed by inhaler weight and tablet count was greater than 90% in both 
groups. The marked reduction in LDL-cholesterol in the group receiving atorvastatin 
(Table 4) provides further evidence of compliance.  The weights of the returned 
inhalers indicate similar compliance with the inhaled beclometasone treatment. 
 
DISCUSSION  
 
In this randomized controlled study we found no improvement in the atorvastatin 
group compared to the placebo group in lung function in smokers with mild to 
moderate asthma, whereas there was an improvement in ACQ and AQLQ scores at 4 
weeks. Atorvastatin treatment had no anti-inflammatory effects on induced sputum 
cell counts or on selected sputum or circulating blood mediator levels. 
 
Three previous randomized controlled crossover clinical trials reported an absence of 
clinical benefit with short-term statin therapy on asthma symptoms or lung function in 
non-smokers with asthma[9-11]. The lack of improvement in PEF, FEV1 or airway 
responsiveness to methacholine in asthmatic smokers following atorvastatin supports 
the conclusions of these earlier studies that statins do not have a short-term beneficial 
effect on lung function in asthma irrespective of smoking status.  
 
In addition to poor symptom control, smokers with asthma have worse asthma-
specific quality of life scores[31]. The AQLQ is a well validated score of subjective 
well being and improving this index is an important goal of asthma management[32]. 
As one of a number of outcome measure we found a mean between-group difference 
  
12
in change from baseline in AQLQ score of 0.52 at 4 weeks, which is just greater than 
the minimal clinically significant change in score of 0.5[33]. The individual AQLQ 
domains for symptoms and emotions also crossed this threshold. The improvement in 
AQLQ score with atorvastatin is comparable to that reported with long-acting β-2 
agonist therapy[34] and with leukotriene receptor antagonist therapy in non-smokers 
with asthma[35]. The non-significant mean improvement in ACQ score of -0.37 did 
not reach the minimum important reduction threshold of -0.5[36]. Improvements in 
subject-centered outcomes with interventions in asthma are usually associated with 
better lung function, although this is not always the case. For example, clinically 
important improvements in the AQLQ score were observed in a trial comparing 
different formulations of inhaled beclometasone[37] and in a double-blind sham-
controlled trial of bronchial thermoplasty[38] while in both studies conventional 
clinical indices of lung function and asthma control were similar.  
 
Statins restore corticosteroid sensitivity in patients with asthma[14, 15], possibly by 
restoring HDAC activity[16] or by increased induction of indoleamine 2, 3-
dioxygense resulting in increased secretion of the anti-inflammatory cytokine IL-
10[15]. Statins also inhibit IL-17 expression and secretion from human Th17 
cells[39], which have been implicated in causing corticosteroid resistance[40]. Based 
on these studies we wished to determine whether atorvastatin might restore sensitivity 
to corticosteroids and had hoped to observe a beneficial effect of atorvastatin and 
inhaled beclometasone compared to inhaled beclometasone alone, but found no 
significant effect in outcome measures at the 8 week time point. It is possible that 4 
weeks was not long enough to demonstrate a synergistic effect, although in previous 
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studies a 4 week treatment period was long enough to show the potentiating effects of 
low dose theophylline on corticosteroid sensitivity in smokers with asthma[41].   
 
Statins have pleiotropic properties including anti-inflammatory and immuno-
modulatory effects [5] that may be beneficial in the treatment of chronic inflammatory 
airway diseases[6].  The anti-inflammatory effects of statins are thought to be 
mediated by inhibition of the isoprenylation of small G-protein signalling molecules 
and by prevention of lipid raft formation, pathways involved in cell proliferation, 
activation and oxidative stress. Statins have immune modulating properties in animal 
models of allergic asthma[7, 8] and COPD[12, 13]. In our study, a limited 
investigation of circulating and airway inflammatory cells and mediators failed to 
show any effects of atorvastatin therapy on inflammatory biomarkers including CRP, 
despite good drug compliance and significant reduction of serum lipid markers.   
 
There are several limitations of the study. Firstly, if fewer than three days of data were 
recorded during the seven days immediately preceding each study visit, patient diary 
entries for morning PEF were substituted in place of the missing value, which raises 
the possibility of increased variability in PEF measurements. However this procedure 
was performed in a minority of PEF measurements used in the analysis and is unlikely 
to have influenced the PEF result. Secondly, while questionnaire scores were not 
significantly different at baseline, it is possible that the slight difference in the 
proportion of participants taking LABA prior to screening may have had an effect on 
subsequent measurements of asthma control. The short duration of treatment with 
atorvastatin may have missed an effect on clinical or inflammatory outcomes. Future 
studies should assess whether treatment with statins influence outcome measures such 
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as exacerbation rate and decline in lung function in smokers with asthma and in 
individuals with more severe disease. Statins have an inhibitory effect on human 
airway smooth muscle cell proliferation[42] and indices of airway remodelling[43-
45]. It is possible that the administration of atorvastatin therapy for a longer duration 
of time may improve outcome measures of airway remodelling in asthma’  
 
Conclusion 
 
In conclusion, short-term treatment with atorvastatin does not improve lung function 
in smokers with mild to moderate asthma, but may improve asthma quality of life. 
Further trials using statins in asthmatic smokers are indicated. 
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Table 1: Demographics and clinical baseline characteristics  
 
 
 Atorvastatin 
(n=36) † 
 
Placebo 
(n=32) † 
Age, years   40.4 (34.8,45.5) 
 
43.0 (38.1,52.0) 
 
Male sex, n (%) 15 (41.7%) 15 (46.9%) 
Smoking history (pack years) 24 (14,34) 21 (10,30) 
Duration of asthma symptoms, 
years 24.0 (14.5,32.5) 
 
19.5 (12.5, 38.5) 
 
Atopic, n (%) 
 
Total IgE (IU/ml) 
18 (54.5%) 
 
82 (19,192) 
21 (67.7%) 
 
197 (76,517) 
Use of inhaled corticosteroid at 
screening , n (%) 
 
Equivalent beclometasone dose at 
screening, µg 
 
Use of LABA at screening, n (%) 
 
19 (52.8%) 
 
 
100 (0,400) 
 
 
8 (22.2%) 
 
 
16 (50.0%) 
 
 
200 (0,800) 
 
 
14 (43.8%) 
 
Pre-bronchodilator FEV1 % 
predicted 84 (71,98) 79 (65,92) 
 
FEV1 % reversibility  
 
11 (6,16) 
 
12 (8,19) 
 
Serum cotinine (ng/mL) 85 (78,90) 82 (79,94) 
 
 
Definition of abbreviations: FEV1, Forced Expiratory Volume in one second; LABA, 
long-acting beta2-agonist  
Data represented as median (IQR) unless specified.   
† Number of randomized subjects with at least one post-baseline assessment of PEF 
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Table 2: Clinical outcomes after atorvastatin treatment or placebo  
 
 
Baseline 4 weeks 8 weeks Variables 
Atorvastatin 
(n=36) 
Placebo 
(n=32) 
Atorvastatin 
(n=34) 
Placebo 
(n=30) 
†Treatment 
difference, 
atorvastatin 
minus placebo 
(95% CI) 
Atorvastatin 
& ICS 
(n=33) 
Placebo 
&ICS 
(n=27) 
†Treatment 
difference, 
atorvastatin minus 
placebo (95% CI) 
 
Morning PEF 
L/min 
 
381.33 
(138.79) 
 
 
348.99 
(116.49) 
 
 
376.39 
(141.63)  
 
357.65 
(121.38) 
 
-10.67 
(-38.70, 17.37) 
p = 0.449 
 
390.51 
(123.38)  
 
354.64 
(123.70) 
 
10.68 
(-20.29, 41.65) 
p = 0.492 
 
Evening PEF 
L/min 
 
391.9 
(137.1) 
 
375.8 
(118.4) 
 
384.8 
(137.1) 
 
367.4 
(117.2) 
 
 
4.95 (-18.61, 
28.51) 
p = 0.676 
 
400.0 
(140.1)  
 
368.3 
(130.5) 
 
 
25.03 (-2.04, 
52.11) 
p = 0.069 
 
FEV1 pre-
salbutamol, L 
 
2.76 
(0.91) 
2.51 
(0.76) 
 
2.79 
(0.83) 
 
2.59 
(0.74) 
 
-0.01 
(-0.13, 0.11) 
p = 0.872  
 
2.80 
 (0.89)  
 
2.63 
 (0.76) 
 
0.03 
(-0.10, 0.16) 
p = 0.651 
FEV1 post-
salbutamol, L 
 
3.08 
(0.94) 
2.88 
(0.75) 
 
3.02  
(0.88)  
 
2.89  
(0.75) 
 
-0.03 
(-0.13, 0.07) 
p = 0.492 
 
3.02  
(0.90)  
 
2.93  
(0.74) 
 
-0.02 
(-0.12, 0.07) 
p = 0.642 
PC20 methacholine  
geometric mean, 
mg/ml  
  
3.29 
(4.03) 
2.15 
(3.34) 
 
4.12 
(4.86) 
 
2.93 
(5.0) 
 
1.36 
(-1.29, 4.01) 
p = 0.307 
 
5.31  
(6.2)  
 
2.31  
(4.0) 
 
1.37 
(-0.65, 3.40) 
p = 0.179 
ACQ Score  
[6 questions] 
1.86 (1.02) 
 
1.86 (0.82) 
 
1.42 (0.68) 
 
1.91 (1.10) 
 
-0.48  
(-0.84,-0.12) 
p=0.009 
1.29 (0.93) 
 
1.64 (1.10) 
 
-0.37 
(-0.8,0.07) 
p=-0.096 
ACQ score 
[7 questions] 
1.88 
(1.00) 
1.96 
(0.79) 
 
1.50 
(0.67) 
 
 
1.90 
(0.90) 
 
-0.37 
(-0.67, -0.07) 
p=0.016 
 
1.38  
(0.93)  
 
1.77 
 (1.00) 
 
-0.35 
(-0.74, 0.04) 
p=0.081 
AQLQ 
Total score 
5.36 
(1.05) 
5.14 
(1.14) 
5.71 
(0.83) 
5.04 
(1.30) 
0.52  
(0.17, 0.87) 
p=0.005 
5.79 
(1.02) 
5.27  
(1.34) 
0.37  
(-0.02, 0.76)  
p=0.063 
AQLQ Symptoms 
Domain 
4.96  
(1.08)  
4.82  
(1.20) 
5.46  
(0.90)  
 
4.74  
(1.39) 
0.63 
(0.18, 1.09) 
p=0.007 
5.67 
(4.96,6.34) 
4.88 
(3.91,6.5) 
0.42  
(-0.05, 0.89)  
p=0.082 
AQLQ Activity 
Limitations 
Domain 
5.84 
(1.06)  
 
 
5.52  
(1.15) 
5.99 
 (0.90)  
 
 
5.36  
(1.25) 
0.40  
(0.10, 0.71) 
p=0.010 
6.08  
(0.97)  
 
5.58  
(1.29) 
0.31  
(-0.01, 0.63) 
p=0.061 
AQLQ Emotional 
Functions Domain 
5.51  
(1.36)  
 
5.10  
(1.35) 
5.90  
(1.19)  
 
5.02  
(1.62) 
0.60  
(0.10, 1.09) 
p=0.019 
5.87  
(1.39)  
 
5.30  
(1.62) 
0.24  
(-0.26, 0.74) 
p = 0.335 
 
AQLQ 
Environmental 
Stimuli Domain 
5.10 
 (1.30)  
 
5.09  
(1.33) 
5.41 
 (1.18)  
 
5.07 
 (1.44) 
0.34  
(-0.09, 0.77) 
p=0.123 
5.71  
(1.15)  
 
5.13 
(1.47) 
0.55  
(0.07, 1.03) 
p=0.026 
Reliever inhaler 
puffs per 24hrs  
3.19 
(2.55) 
2.94 
(2.93) 
2.58 
(2.67) 
 
3.97 
(5.45) 
-0.66 
(-1.69, 0.37) 
p = 0.205 
2. 13 
(2.63) 
1.99 
(2.33) 
-0.12 
(-1.35, 1.11) 
p = 0.841 
 
 
 
Abbreviations: ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; 
PEF, peak expiratory flow rate; FEV1, forced expiratory volume in one second; Data represented as 
mean (SD) unless otherwise indicated.   
†Treatment difference from analysis of covariance, analysing change from baseline and adjusting for 
baseline value. 
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Table 3: Inflammatory outcomes after atorvastatin treatment or placebo  
 
Baseline 4 weeks 8 weeks Variables 
Atorvastatin 
(n=35) 
Placebo 
(n=32) 
Atorvastatin 
(n=31) 
Placebo 
(n=29) 
Treatment 
difference, 
atorvastatin 
minus 
placebo (95% 
CI) 
Atorvastatin 
& ICS 
(n=32) 
Placebo 
&ICS 
(n=24) 
 
Treatment 
difference, 
atorvastatin 
minus 
placebo (95% 
CI) 
Sputum 
differential cell 
count & 
proportion (%) 
        
Total cell count 
(x104) 
 
 
651.5 
 (547.0, 890.5) 
 
 
620.8 
 (543.2, 758.8) 
 
628.5 
(533.5, 921.5) 
 
602.0 
(512.0, 791.0) 
 
43.0 
(-75.2, 161.1) 
p = 0.469 
 
607.8 
(517.0, 785.5) 
 
658.5 
(563.2, 860.2) 
 
-81.6 
(-177.2,14.0) 
p = 0.093 
Macrophage 
(x104) 
 
Macrophage % 
 
154.5 
(111.5, 263.0) 
 
38.4 
(29.6, 61.3) 
 
179.8 
(87.2, 242.2) 
 
45.1 
(31.8, 58.7) 
 
159.5 
(132.0, 221.0) 
 
45.5  
(31.5, 58.9)  
 
 
142.5 
(81.0, 220.0) 
 
38.5  
(24.6, 54.6) 
 
16.9 
(-27.5, 61.3) 
p = 0.450 
 
4.8 
(-5.9, 15.5) 
p = 0.374 
 
173.2 
(126.2, 247.2) 
 
41.4 
(34.1, 54.9)  
 
174.2 
(122.8, 250.5) 
 
44.2 
(32.3, 59.0) 
 
-3.0 
(-47.6, 41.6) 
p = 0.893 
 
-0.5  
(-9.6, 8.6) 
p = 0.913  
Neutrophil 
(x104)  
 
Neutrophil % 
 
131.0 
(76.0, 232.5) 
 
37.8  
(18.3, 54.2) 
 
122.8 
(56.2, 201.2 
29.9  
(15.0, 49.1) 
 
136.5 
(61.0, 233.5) 
 
33.6  
(18.2, 55.8)  
 
 
99.0 
(69.5, 299.5) 
 
31.5 
 (17.6, 63.2) 
 
-19.2 
(-72.0, 33.6) 
p = 0.470 
 
-4.7 
(-15.7, 6.4) 
p = 0.401 
 
151.8 
(80.5, 211.5) 
 
38.3 
 (23.0, 52.8)  
 
 
149.0 
(78.2, 229.0) 
 
34.9  
(20.7, 49.5) 
 
-8.0 
(-49.4, 33.4) 
p = 0.700 
 
2.1  
(-8.0, 12.1) 
p = 0.680 
Eosinophil 
(x104) 
 
Eosinophil % 
 
3.0 
(0.5, 7.5) 
 
0.6 
(0.1, 2.4) 
 
1.5 
(0.0, 5.8) 
 
0.4 
 (0.0, 1.4) 
 
1.5 
(0.0, 4.5) 
 
0.4  
(0.0, 1.0) 
 
 
1.5 
(0.0, 3.5) 
 
0.3  
(0.0, 1.2) 
 
-3.2 (-8.6, 2.3) 
p = 0.253 
 
-1.0  
(-2.3, 0.3) 
p = 0.138 
 
 
1.3 
(0.3, 5.5) 
 
0.4  
(0.1, 1.1)  
 
 
0.8 
(0, 2.5) 
 
0.2  
(0, 0.6) 
 
0.4 
(-1.6,2.5) 
p = 0.677 
 
0.1  
(-0.4, 0.5) 
p = 0.798 
Lymphocyte 
(x104) 
 
Lymphocyte % 
 
1.5 
(0.0, 3.0) 
 
0.3  
(0.0, 0.7) 
 
0.8 
(0.0, 2.8) 
 
0.2 
 (0.0, 0.7) 
 
0.5 
(0.0, 3) 
 
0.1  
(0.0, 0.7) 
 
 
0.5 
(0.0, 1.5) 
 
0.1 
 (0.0, 0.5) 
 
0.8 
(-0.2, 1.9) 
p = 0.125 
 
0.1  
(-0.2, 0.4) 
p = 0.425 
 
 
0.8 
(0.0, 2.0) 
 
0.2 
(0.0, 0.7) 
 
 
1.3 
(0.0, 2.5) 
 
0.4 
(0.0, 0.6) 
 
-0.1 
(-1.3, 1.1) 
p = 0.865 
 
0.1  
(-0.3, 0.4) 
p = 0.757 
Bronchial 
epithelial cell 
(x104) 
 
Br. epithelial 
cell % 
 
44.0 
(26.0, 90.5) 
 
 
11.5  
(5.9, 26.0) 
 
49.5 
(29.0, 117.0) 
 
 
12.3  
(7.8, 29.2) 
 
33.0 
(18.0, 78.0) 
 
 
8.4 
(5.9, 17.8) 
 
 
37.5 
(24.0, 89.5) 
 
 
9.2 
(5.6, 24.8) 
 
 
20.6 
(-9.6, 50.9) 
p = 0.177 
 
 
1.6 
(-5.9, 9.0) 
p = 0.680 
 
40.0 
(28.0, 75.8) 
 
 
11.2  
(6.8, 22.2) 
 
 
57.8 
(39.5, 92.8) 
 
 
13.3  
(9.2, 22.5) 
 
-10.3 
(-32.7, 12.1) 
p = 0.361 
 
 
-1.3  
(-7.7, 5.1) 
p = 0.679 
 
Sputum 
mediators 
        
Leukotriene B4 
(pg/ml)  
103.1 
(79.7, 185.4) 
172.0 
(106.0, 422.4) 
98.4 
(56.9, 215.2) 
175.2 
(77.0, 336.0) 
-49.4 
(-205.1, 
106.4) 
p = 0.528 
104.9 
(41.9, 151.5) 
159.0 
(81.0, 520.2) 
-231.4 
(-589.5, 126.6) 
p = 0.200 
MPO  
(ng/mL) 
16.5 
(6.4, 39.6) 
27.0 
(10.6, 40.6) 
16.4 
(9.0, 30.5) 
20.6 
(10.6, 34.1) 
-16.5 
(-48.0, 15.0) 
p = 0.298 
14.8 
(6.4, 34.5) 
28.1 
(8.9, 68.8) 
-111.2 
(-264.8, 42.5) 
p = 0.152 
Interleukin-6 
(pg/ml) 
139.5 
(33.9, 276.5) 
220.4 
(70.0, 498.5) 
109.3 
(33.9, 351.5) 
144.4 
(40.3, 391.6) 
-5.6 
(-254.1, 
243.0) 
147.2 
(35.9, 223.0) 
122.0 
(34.1, 518.6) 
-22.5 
(-247.3, 202.3) 
p = 0.841 
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p = 0.964 
 
Interleukin-8 
(pg/ml) 
 
813.1 
(238.8, 3000.0) 
3000.0 
(426.1, 3000.0) 
408.5 
(179.7 ,3000.0) 
1686.0 
(353.2, 3000.0) 
-453.4 
(-1071.9, 
165.1) 
p = 0.127 
386.5 
(180.7, 3000.0) 
541.5 
(239.4, 3000.0) 
172.3 
(-600.8,945.4) 
p = 0.656 
Interleukin-10 
(pg/ml) 
13.6 
(1.0, 126.9) 
13.0 
(1.2, 80.9) 
1.8 
(0.3, 105.3) 
15.4 
(0.8, 53.4) 
27.5 
(-53.2, 108.2) 
p = 0.497 
6.1 
(0.7, 72.6) 
4.6 
(0.7, 62.9) 
-4.2 
(-132.8, 124.5) 
p = 0.948 
 
 
Serum 
biomarkers 
        
hs-CRP (mg/L) 
2.8 
(1.6, 4.0) 
3.6 
(1.5, 6.9) 
2.6 
(1.6, 5.0) 
2.8 
(1.4, 5.6) 
0.9 
(-4.1, 5.9) 
p = 0.718 
1.9 
(1.0, 4.1) 
2.1 
(1.0, 5.1) 
0.6 
(-2.8, 3.9) 
p = 0.731 
Interleukin-6 
(pg/ml) 
2.0 
(0.2, 4.1) 
2.6 
(0.2, 30.0) 
2.7 
(0.2, 11.0) 
1.8 
(0.2, 26.0) 
-9.1 
(-20.8, 2.7) 
p = 0.127 
0.4 
(0.2, 8.8) 
3.1 
(0.2, 21.2) 
16.7 
(-29.5, 62.8) 
p = 0.472 
 
 
Abbreviations: CRP, C-reactive protein; MPO, myeloperoxisade; Mediator levels 
pg/ml unless otherwise indicated. Data represented as median (IQR) unless otherwise 
indicated.   
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Table 4 Serum biochemical outcomes after atorvastatin treatment or placebo 
 
 
 
Baseline 8 weeks Variables 
Atorvastatin 
(n=35) 
Placebo 
(n=32) 
Atorvastatin 
& ICS 
(n=32) 
Placebo 
&ICS 
(n=25) 
Treatment difference, 
atorvastatin minus 
placebo (95% CI) 
 
Total cholesterol 
(mmol/l) 
 
 
5.15 (0.89) 
 
5.67 (1.12) 
 
3.62 (0.76) 
 
5.34 (0.90) 
-1.55 
(-1.88, -1.23)  
P<0.0001 
Triglycerides 
(mmol/l) 
 
1.59 (0.87)  
 
2.18 (1.41) 
 
1.02 (0.35) 
 
 
1.74 (1.29) 
-0.49  
(-0.87, -0.11)  
P=0.013 
LDL-cholesterol 
(mmol/l) 
 
3.19 (0.82) 
 
3.49 (0.99) 
 
1.89 (0.62) 
 
 
3.46 (0.87) 
-1.50  
(-1.88, -1.13)  
P<0.0001 
HDL-cholesterol 
(mmol/l) 
 
1.24 (0.35) 
 
1.26 (0.31) 
 
1.29 (0.35) 
 
 
1.23 (0.27) 
0.03  
(-0.06, 0.13)  
p = 0.497 
Alkaline 
phosphatase (IU/l) 
 
83.33 (31.36) 
 
75.16 (21.04) 
 
98.62 (91.26) 
 
77.16 (19.58) 
5.94  
(-15.67, 27.54)  
p = 0.584 
 
ALT (IU/l) 
 
17.58 (9.27) 
 
22.50 (11.88) 
 
 
22.00 (14.37) 
 
24.04 (11.70) 
3.67 
(-1.84, 9.18)  
p = 0.188 
 
 
 
Abbreviations: ALT, alanine aminotransferase  
Data represented as mean (SD).  
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FIGURE LEGENDS 
 
Figure 1: Flow of patients through study  
 
Figure 2: Change from baseline for both treatment groups in (a) morning PEF 
[L/min], (b) ACQ score, (c) AQLQ total score at 4 weeks. P values are for 
comparisons of the mean change from baseline between the two treatments.  
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